What should be in place before a first orforglipron vial arrives from Zhuhai?

Stated plainly: orforglipron · Zhuhai.

I am trying to build something sustainable rather than something thorough that I will abandon.

I have already decided the broad direction; this is about the specifics.

What would you do, and what would make you change course?

The short version: independent testing, conservative titration, sterile-ish technique, a written record and a clinician who knows.

Tell a clinician. The most common reason a problem becomes serious in this space is that the person having it withheld the relevant fact from the person who could have helped.

More usefully, have a plan for stopping before you start, including what you would do with the remaining material and how you would tell someone what you had taken.

The caveat is that harm reduction reduces harm and does not eliminate it, and the category risk of unapproved material cannot be mitigated away.

Keep a written log with lot numbers. It is what a professional can actually use.

The honest answer is that the single highest-value action is testing your own material, and the second is telling a clinician.

Do not combine unknowns. Adding a second unverified compound while assessing the first makes any observation uninterpretable and doubles the exposure.

Keep a written log: date, dose, lot, site, and anything noticed. It converts an anecdote into a record and is what makes any later consultation productive.

Start lower and go slower than the label. Time costs nothing here.

Worth being precise here: keeping a record turns a vague worry into something a professional can act on.

Handling risk is reduced by aseptic technique, minimising stopper entries, refrigerating after reconstitution and discarding on any change in appearance. None of it makes a preparation sterile.

Nothing here is medical advice, and research-use compounds are not approved for human use in any jurisdiction.

Learn the handful of symptoms that end the discussion and start a clinical one.

edited 13 Jan 2025 by lyoph_cake — corrected a unit error in the worked example

Answering this needs to know what is already in place, because the marginal value of each step depends on which are missing.

Pharmacological risk is reduced by starting below the lowest licensed step and escalating more slowly than the label schedule. Time is the cheapest resource in this whole calculation.

Withheld information is a recognised barrier to effective clinical assessment, and disclosure changes management in a substantial fraction of cases.

This site sells nothing, is affiliated with no supplier and takes no payment from any of them.

Test your own material. Everything else is downstream of knowing what it is.